Showing 1,121 - 1,140 results of 5,484 for search '"Pharmaceutics"', query time: 0.06s Refine Results
  1. 1121
  2. 1122

    Potential and Comparative Tablet Disintegrant Properties of Pectin Obtained from Five Okra Genotypes in Ghana by Frederick William Akuffo Owusu, Mariam El Boakye-Gyasi, Jacob Kwaku Agbenorhevi, Marcel Tunkumgnen Bayor, Kwabena Ofori-Kwakye

    Published 2021-01-01
    “…Okra pectin has been studied as a potential excipient in tablet formulations for pharmaceutical industries. Okra is widely grown and available in Ghana and other parts of the world. …”
    Get full text
    Article
  3. 1123
  4. 1124
  5. 1125
  6. 1126

    In Vitro Evaluation of Native Taro Boloso-I Starch as a Disintegrant in Tablet Formulations by Tamrat Balcha Balla, Nisha MaryJoseph, Anteneh Belete

    Published 2021-01-01
    “…The tablets exhibited improved crushing strength, friability, in vitro disintegration time, and disintegration efficiency ratio which suggest the novel applicability of the native Taro Boloso-I starch as an efficient pharmaceutical tablet disintegrant.…”
    Get full text
    Article
  7. 1127
  8. 1128
  9. 1129
  10. 1130
  11. 1131
  12. 1132
  13. 1133

    A New Combination Formula for Treatment of Fungal Keratitis: An Experimental Study by Hala Mohamed El-Mofty, Mohamad Amr Salah Eddin Abdelhakim, Mohamed Farid El-Miligi, Mohamed A. El-Nabarawi, Islam Ahmed Hamed Khalil

    Published 2014-01-01
    “…Experimental study with the following outcome measures. Pharmaceutical Evaluation. Mucoadhesive gels containing ketoconazole and ketorolac were used. …”
    Get full text
    Article
  14. 1134
  15. 1135

    Natural killer cell engagers for cancer immunotherapy by Shahryar Khoshtinat Nikkhoi, Geng Li, Arash Hatefi, Arash Hatefi

    Published 2025-01-01
    “…This review article critically examines the strategies for engineering bi-, tri-, and multi-specific NKCEs for cancer immunotherapy, providing an in-depth analysis of the latest advancements in NKCE platform technologies currently under development by pharmaceutical and biotech companies and discussing the preclinical and clinical progress of these products. …”
    Get full text
    Article
  16. 1136
  17. 1137
  18. 1138
  19. 1139
  20. 1140